Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Tuesday, August 4, 2026

Snapshot: Aug 4, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Tue, Aug 4, 2026 Complacency High

Tech-led mega-rally with broad-market complacency as VIX cratered 20%, NASDAQ soared 6.9%, and extreme single-stock dispersion sparked 50+ names surging past 25%.

55% NASDAQ and tech rallied 6.9% in a complacency regime as fear evaporated—VIX plunged 20% on strong earnings beats from mega-cap names like PLTR (+29%), ZBRA (+27%), and APPS (+28%), signaling risk appetite has fully returned despite calm underlying volatility.
30% High dispersion chaos beneath the surface: 100 stocks moved >25%, with Healthcare dominating gainers at 32% share, led by blockbuster earnings stories like IBTA (+51% on 7-Eleven partnership), INFU (+33% on oncology revenue surge), and MED (+34% on coach productivity gains).
15% Losers skewed Healthcare (26% of decliners) with severe crashes in micro-caps like NXTT (-73%) and RAIN (-68%) lacking reported catalysts, while news-grounded selloffs hit AHCO (-38% on cost overruns), BETR (-37% on CEO transition), and REZI (-28% on spin-off completion).

Healthcare drove 32% of gainers 5 names returned after long absences JDZG · 3-day losers streak PN · 3-day losers streak IBTA — first appearance SAC.WT — first appearance

Market Regime

Tue, Aug 4, 2026 Risk-On conf: medium macro · prototype

+37

Tailwind −100 … +100 · + tailwind / − headwind

VIX16.5 p32 Drawdown0.0% Held2d · nascent SinceAug 3

Top drivers: S&P vs 20d avg ▲ VIX percentile ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Tue, Aug 4, 2026 13

S&P 500

7,736.52

+307.74

+4.14%

Dow Jones

54,085.88

+1,338.56

+2.54%

NASDAQ Composite

26,584.99

+1,708.08

+6.87%

NASDAQ 100

29,733.16

+1,970.03

+7.10%

DJ US Total Market

76,623.37

+2,997.02

+4.07%

Russell 1000

4,213.69

+165.43

+4.09%

S&P MidCap 400

3,868.41

+70.04

+1.84%

Russell 2000

3,036.98

+83.18

+2.82%

Russell 2500

1,295.77

+24.67

+1.94%

Russell 3000

4,399.97

+170.55

+4.03%

Nasdaq Financial-100

7,574.83

+63.96

+0.85%

NIFTY 50

24,614.90

+364.70

+1.50%

VIX

16.50

−4.16

-20.14%

Biggest Gainers

Tue, Aug 4, 2026 50

ZJYL

JIN MEDICAL INTERNATIONAL LTD. - Ordinary SharesHealthcare

$1.94+$1.41

+70.9%

NASDAQ · Mkt cap $24 M

Jin Medical reported first-half fiscal 2026 financial results on August 4, likely triggering a 70.85% surge in a micro-cap stock that may have been oversold or awaiting earnings clarity.

The headline confirms that Jin Medical, a NASDAQ-listed provider of rehabilitation medical equipment in China, released H1 FY2026 financial results on the exact date of the move. The headline is truncated and does not specify whether results beat or missed expectations, revenue trends, profitability metrics, or forward guidance. For a micro-cap stock trading at $1.94 with minimal institutional coverage, an earnings release alone can spark outsized moves, particularly if the company had been under pressure or if results surprised positively. The timing of the announcement (20:30 UTC, after US market hours) suggests the move occurred in after-hours trading or at the open the following trading session. Without the full earnings details—earnings per share, revenue growth, margins, guidance—we cannot confirm whether the move reflects genuine operational improvement or repositioning in a thinly-traded name. Reasonable inference: the earnings likely contained at least neutral-to-positive surprises relative to depressed expectations, or the market rewarded the company for simply delivering results in a stock that had been heavily oversold.

SXTC

China SXT Pharmaceuticals IncHealthcare

$0.13+$0.05

+67.3%

NASDAQ · Mkt cap $2.4 M

No news was reported in the last 48 hours for SXTC, so the 67% gain on August 4 likely stems from technical factors, delayed news dissemination, or speculation rather than a newly announced corporate event.

The absence of recent headlines makes it difficult to pinpoint a specific catalyst for the sharp 67% rally. SXTC is a micro-cap pharmaceutical stock trading at $0.13, a price range historically associated with high volatility and susceptibility to technical rebounds, short-covering, or retail interest following extended weakness. Without confirmed news, the move could reflect a delayed market reaction to an earlier announcement not yet picked up by major feeds, a clinical trial development, regulatory filing, or simply technical momentum in a thinly traded name. Micro-cap biotech stocks in this price range also sometimes experience large single-day moves on very low volume or speculative activity unconnected to fundamental catalysts.

TNMG

TNL Mediagene Ordinary SharesCommunication Services

$0.48+$0.20

+58.7%

NASDAQ · Mkt cap $1.1 M

TNL Mediagene announced a partnership with Miro for AI-powered organizational design services in Japan and disclosed a strategic alternatives review with financial advisors engaged, likely driving investor optimism about growth and potential M&A or restructuring upside.

Two material headlines arrived within 24 hours. The partnership announcement signals revenue diversification and entry into an AI-services market segment, which appeals to growth-focused investors in a beaten-down stock trading near penny-stock territory. More significantly, the establishment of a special committee to evaluate strategic alternatives with Imperial Capital engaged as financial advisor typically signals openness to transformative transactions, asset sales, or restructuring, which can unlock value for shareholders in underperforming companies. At $0.48, the stock has likely suffered steep losses prior to this snapshot, making strategic alternatives newsworthy enough to attract short-covering and speculative buyers. The 58.75% single-day jump is consistent with a micro-cap responding to credible growth and M&A-related catalysts, though absolute conviction should be tempered until more details on either the partnership's commercial potential or the scope of alternatives emerge.

IBTA

Ibotta, Inc.Technology

$37.23+$12.60

+51.2%

NYSE · Mkt cap $867 M

Ibotta surged 51% on strong Q2 earnings that beat expectations and a major exclusive partnership deal with 7-Eleven covering over 11,500 US stores and 100 million loyalty members, marking the company's return to revenue growth.

The headlines establish two concrete catalysts announced on August 3-4, 2026. First, Ibotta beat Q2 revenue and earnings estimates, with the company reporting 3.3% year-over-year revenue growth to $88.91 million—notably the first positive annual revenue growth since Q1 2025, ending a period of decline. The earnings beat was driven by a 27% surge in third-party publisher revenue. Second, and likely equally material, Ibotta announced it became the exclusive CPG offers provider for 7-Eleven, 7NOW, and Speedway apps, a partnership that provides access to 11,500+ US locations and over 100 million loyalty members. This represents a major customer win and revenue opportunity for the Performance Network platform. The 51% one-day gain reflects investor relief that the company has stabilized revenue and excitement around near-term growth prospects from the 7-Eleven contract.

GCTK

GlucoTrack, Inc.Healthcare

$0.59+$0.19

+48.2%

NASDAQ · Mkt cap $3.7 M

The provided news is unrelated to GCTK; the 48% gain likely reflects a specific catalyst involving GlucoTrack itself that is not captured in the available headlines, such as clinical data, a partnership announcement, or technical factors in a micro-cap stock.

The only headline provided concerns Lōkahi Therapeutics and its ai² Futures Lab platform for biopharma pipeline development. This is a corrected press release from August 3rd unrelated to GlucoTrack, a diabetes-monitoring company. No news directly tied to GCTK appears in the RSS feed excerpt. A 48% single-day gain in a sub-dollar stock is substantial and typically driven by a specific catalyst: clinical trial results, FDA approval or guidance, a partnership or licensing deal, funding announcement, or short-covering in a thinly-traded micro-cap. Without direct headlines about GCTK, we cannot confirm the cause. Micro-cap stocks are also prone to momentum-driven rallies and low-volume volatility, which could amplify moves absent major news.

CDTG

CDT Environmental Technology Investment Holdings Limited ordinary sharesIndustrials

$1.16+$0.38

+41.6%

NASDAQ · Mkt cap $9.9 M

No news headlines were found in the last 48 hours, so the 41.6% gain on August 4, 2026 cannot be attributed to a disclosed event. The jump likely reflects technical or sentiment-driven trading in a low-priced stock.

The absence of recent news headlines is notable given the magnitude of the move. CDTG is a small-cap environmental technology investment company trading at $1.16, a price point where stocks can experience outsized percentage moves on modest absolute volume or momentum. Without disclosed catalysts such as earnings, contract awards, regulatory approvals, or capital announcements, the move falls into a category typical of lower-priced equities: short covering, technical breakouts, retail accumulation, or delayed market reaction to older news. It is also possible that news exists but was not captured in the Yahoo Finance RSS feed shown. The environmental technology sector has seen investor interest in recent years, though we cannot determine if sector trends or company-specific sentiment drove this particular move.

OPAD

Offerpad Solutions Inc.Real Estate

$4.96+$1.44

+40.9%

NYSE · Mkt cap $20 M

Offerpad surged 40.91% following Q2 earnings that revealed strong operational improvements—dramatic margin gains, 145% quarterly growth in contribution profit per transaction, and accelerating contract signings—despite missing revenue estimates and delivering an earnings surprise of -23.13%.

The market appears to have rewarded forward-looking operational metrics and margin trajectory over headline earnings misses. Q2 results showed revenue fell 9.29% below estimates at $77.7 million (down 51.5% year-over-year), and earnings came in 23.13% below expectations. However, the earnings call highlights emphasized meaningful margin expansion: adjusted EBITDA loss narrowed to $6.2 million and contribution profit per transaction surged 145% quarter-over-quarter, while June contract signings reached 256 units. The messaging "The Buying Engine Is Back On" signals management confidence in a recovery trajectory. For a turnaround-story small-cap real estate tech company, demonstrating that losses are shrinking and per-transaction economics are improving can drive strong relief rallies even when absolute revenue disappoints, as it suggests the worst may be behind them.

SAC.WT

Safeguard Acquisition Corp. WT

$0.60+$0.17

+39.5%

NXTC

NextCure IncHealthcare

$5.91+$1.62

+37.8%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the 37.76% jump cannot be attributed to a specific announced catalyst. The gain likely stems from technical trading, delayed news digestion, or market rumors.

NextCure Inc experienced a significant single-day surge of 37.76% without any identifiable news catalyst in the recent headlines feed. This creates a gap between the price action and available information. For a clinical-stage or small-cap biotech company like NXTC, such moves typically occur following FDA decisions, trial result announcements, partnership deals, or strategic shifts. In the absence of headline confirmation, the move could reflect several mechanisms: a delayed market reaction to news released outside the monitored window, technical reversal from oversold conditions, options-driven momentum, short covering, or unverified market rumors circulating on social media or trading forums. Without access to company filings, insider transactions, or broader market context on the day, pinpointing the specific trigger is not possible from the evidence provided.

XGN

Exagen IncHealthcare

$6.48+$1.73

+37.0%

NASDAQ · Mkt cap $180 M

Exagen reported record Q2 2026 revenue of $19.9 million, nearly achieved adjusted EBITDA breakeven, and raised full-year guidance, driving the 37% surge.

The earnings headlines establish a consistent positive narrative: record quarterly revenue, a narrowed net loss of nearly 30%, adjusted EBITDA losses cut to just $0.1 million, and raised full-year revenue guidance to $72–$75 million. The company also beat both earnings and revenue estimates significantly (31.58% and 10.58% respectively). Growth drivers cited include higher AVISE CTD test volume, improved average selling price, and Pharma Services revenue. For a small-cap diagnostics company trading under $10, achievement of near-breakeven adjusted EBITDA combined with a raised outlook represents a major inflection point toward profitability. The timing of the announcement (morning of August 4th) and magnitude of beats likely triggered institutional and retail interest simultaneously, explaining the top-10 ranking among daily gainers.

TSAT

Telesat CorporationTechnology

$54.81+$14.59

+36.3%

NASDAQ · Mkt cap $2.4 B

Telesat landed a record $1.9 billion Canadian military satellite contract announced August 4th, the largest in the company's history, driving the 36% gain as investors reacted to the substantial revenue win and constellation expansion.

Telesat announced a US$1.9 billion contract with the Government of Canada for military Ka-band Arctic connectivity, marking the largest revenue contract in the company's six-decade history. The deal expands the Telesat Lightspeed constellation from 156 to 225 satellites, representing a 44% capacity increase. Additionally, MDA Space secured a $474 million subcontract to build satellites for this project, signaling supply chain momentum. All announcements occurred on August 4th during market hours or shortly after, providing clear visibility to investors about a transformational contract win. The magnitude of the deal, its strategic nature for Canadian military sovereignty, and the concrete capacity expansion plan provide substantial positive catalysts that would justify a significant single-day stock appreciation for a satellite operator dependent on long-term government contracts.

GENVR

Gen Digital Inc. Contingent Value Rights

$2.67+$0.75

+34.1%

NASDAQ

Gen Digital launched the Fearless Planet Index on August 3, which appears to be the only recent catalyst. Whether this announcement directly drove the 34% gain in the CVR (contingent value rights) is unclear without details on market reaction or underlying stock performance.

The only headline in the past 48 hours is Gen Digital's launch of the Fearless Planet Index, described as a cybersecurity and digital freedom benchmarking tool. The announcement itself contains no obvious value-accretive details—no financial metrics, partnerships, or strategic shifts are specified. CVRs are typically volatile and react sharply to news affecting the parent company's prospects, but this particular announcement reads as a product launch or index introduction rather than material business development. The 34% jump may reflect underlying strength in Gen Digital (GEN) stock itself, market enthusiasm for the index framework, short covering in the thinly-traded CVR, or a delayed market reaction to earlier news not captured in the provided headlines. Without clarity on GEN's price action or broader context, the link between the index launch and the CVR move remains speculative.

ELPW

Elong Power Holding Limited Class A Ordinary SharesIndustrials

$0.16+$0.04

+33.9%

NASDAQ · Mkt cap $2.2 M

Elong Power announced the closing of a US$1.38 million public offering on August 4, coinciding with a 33.89% gain, suggesting investor optimism around the capital raise or relief at completion of the offering process.

Elong Power Holding Limited, a lithium-ion battery energy storage systems provider, announced the pricing of a US$1.38 million public offering on August 3 and the closing of that same offering on August 4. The stock jumped 33.89% on the closing day. The timing strongly suggests the market reacted positively to either the successful completion of the capital raise, confidence in the company's ability to fund operations and growth, or technical factors related to the offering itself such as short covering or relief from offering-related downward pressure. However, the headlines do not provide details on the offering price relative to prior trading levels, the use of proceeds, or any forward guidance that might explain the magnitude of the gain. For a micro-cap stock trading at $0.16, relatively small volume shifts can drive large percentage moves, so caution is warranted in attributing causality.

MED

Medifast IncConsumer Cyclical

$13.02+$3.27

+33.5%

NYSE · Mkt cap $129 M

Medifast beat Q2 earnings expectations despite a 27.6% revenue decline, driven by a 41% jump in coach productivity and new Trilivy brand launch targeting metabolic health, signaling a strategic turnaround that sparked the 33.54% surge.

Medifast reported a narrower-than-expected loss on August 3rd and beat revenue estimates by 1.14%, which initially drove a 12.8% jump. The deeper narrative centers on operational inflection: while the active coach base continues to shrink amid GLP-1 medication adoption, the company achieved a remarkable 41% improvement in coach productivity, partially offsetting revenue pressure. Management's strategic pivot to the Trilivy brand and guidance toward profitability by Q4 2026 appears to have resonated strongly with investors as evidence of a viable path forward in a challenged market. The stock's continued strength into August 4th reflects confidence that these productivity gains and the new product line represent genuine business stabilization rather than terminal decline.

MYNZ

Mainz Biomed B.V.Healthcare

$1.52+$0.38

+33.3%

NASDAQ · Mkt cap $18 M

No news headlines were found in the last 48 hours, so the cause of the 33% jump cannot be attributed to a specific announced event. The move may reflect technical trading, delayed news dissemination, or market speculation.

Mainz Biomed is a molecular diagnostics company focused on colorectal cancer screening, and a 33% single-day gain ranking it 15 nationwide is substantial. The absence of any headlines in the Yahoo Finance RSS feed over the past 48 hours is notable and suggests either that news coverage was delayed or spotty, or that the move was driven by factors other than a major corporate announcement. For small-cap biotech stocks like MYNZ, typical catalysts include clinical trial results, regulatory approvals, partnership announcements, or shifts in analyst sentiment. The stock's low price of $1.52 also means it may be more susceptible to retail trading activity or short-covering rallies. Without headline evidence, the most likely explanations are either an unindexed or delayed news item, a technical rebound after prior weakness, or increased institutional or retail buying pressure unconnected to a specific event.

AFJKR

Aimei Health Technology Co., Ltd Right

$0.12+$0.03

+33.3%

INFU

InfuSystem Holdings IncHealthcare

$12.22+$3.04

+33.1%

NYSE · Mkt cap $243 M

InfuSystem delivered a strong Q2 earnings beat with record revenue of $36.9M, oncology revenue surpassing $20M, and wound care surging 154%, driving the 33% gain.

The stock jumped on the heels of InfuSystem's second-quarter earnings announcement, which exceeded analyst expectations on both earnings (up 25%) and revenue (up 1.19%). The company reported record quarterly revenue of $36.9M, with particularly strong performance in its oncology segment which crossed the $20M threshold, and exceptional growth in wound care with a 154% year-over-year surge. The earnings call highlights released later in the day reinforced these points while noting the company is managing a GE contract restructuring, which appears not to have derailed investor confidence given the magnitude of the move. The combination of record top-line performance, significant oncology expansion, and explosive wound care growth likely triggered broad-based buying, with the +25% earnings surprise being the primary catalyst for institutional and retail participation.

BOCN

Blue Ocean Acquisition CorpBasic Materials

$0.48+$0.12

+32.1%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the 32% gain cannot be attributed to a specific announced event. The move may reflect technical trading, a delayed market reaction to an older news item, or sector momentum in blank-check acquisition vehicles.

Blue Ocean Acquisition Corp is a SPAC (special purpose acquisition company), a class of security that can experience sharp intraday moves on low volume and minimal news flow. SPACs trade on sentiment about potential merger targets, redemption dynamics, and broader market appetite for blank-check structures. Without any recent headlines to explain the jump, the most likely hypotheses are that this was a technical bounce off support levels given the stock's very low price, repositioning by short-term traders, or an earlier announcement that took time to gain traction in the market. BOCN's position at $0.48 suggests it may face delisting risk, which can create both distressed selling and speculative buying pressure depending on redemption or merger timelines that may not have generated formal news coverage.

XOS

Xos, Inc.Industrials

$2.65+$0.69

+31.5%

NASDAQ · Mkt cap $41 M

Xos released a white paper identifying a 117 MWh power gap for LA28 Olympic venues, positioning the company's zero-emission technology as a solution to meet renewable energy commitments without permanent infrastructure.

The white paper announcement directly addresses a specific infrastructure gap for the 2028 LA Olympics, highlighting a strategic need that aligns with Xos's core business in zero-emission vehicles and energy systems. The timing and specificity of the 117 MWh figure suggests the company is positioning itself as a provider to fill this identified gap. This type of high-profile infrastructure narrative, especially one tied to a major upcoming event and sustainability commitments, can attract investor interest in an EV/clean-tech stock. The 31.51% single-day surge suggests the market interpreted this announcement as concrete evidence of addressable demand rather than speculative positioning.

Wayfair IncConsumer Cyclical

$116.10+$26.45

+29.5%

NYSE · Mkt cap $13 B

Wayfair surged 29.5% following a better-than-expected Q2 earnings beat, with accelerating US revenue growth of 8.7%, record EBITDA margins, strong specialty brand performance (Perigold up 35%), and positive Q3 guidance fueling investor optimism.

Wayfair reported second-quarter results that exceeded Wall Street expectations across multiple dimensions. US revenue growth of 8.7% marked the best performance since 2021, while the company achieved its best EBITDA margin since 2021 and free cash flow of $301 million, described as the strongest since 2020. The company's strategic initiatives are showing tangible results: brick-and-mortar store expansion and higher-end product offerings (particularly through its Perigold brand, which surged over 35%) are driving consumer demand. Management provided Q3 guidance for high single-digit revenue growth, signaling sustained momentum. The combination of a quantitative earnings beat, operational margin improvement, and positive forward guidance typically generates significant single-day gains for cyclical retailers, especially those perceived as having turned a corner operationally.

IMC

IMC Rare Earths LtdBasic Materials

$8.20+$1.86

+29.5%

PAY

Paymentus Holdings, Inc.Technology

$44.65+$10.14

+29.4%

NYSE · Mkt cap $4.6 B

Paymentus (PAY) surged 29.4% on August 4 following a strong Q2 2026 earnings beat announced the prior evening, with record revenue of $360.7M (up 28.8% YoY) and adjusted EBITDA up 54%, plus better-than-expected forward guidance.

The stock's jump aligns directly with Paymentus's Q2 earnings announcement on August 3 after market close. The company delivered material outperformance across three dimensions: revenue beat analyst expectations by 4.45%, earnings per share beat by 25%, and management provided Q3 guidance that also exceeded Street consensus. The company reported record quarterly revenue driven by higher transaction volumes, new biller customer launches, and growth from existing customers. Adjusted EBITDA growth of 54% year-over-year significantly outpaced revenue growth of 28.8%, demonstrating improving operational leverage and margin expansion. One outlet noted the stock had already jumped 11.9% immediately after the earnings release on August 3, with the additional 17+ percentage point move on August 4 likely reflecting sustained momentum and positive analyst updates after the call.

PLTR

Palantir Technologies IncTechnology

$162.63+$36.72

+29.2%

NASDAQ · Mkt cap $423 B

Palantir surged 29% after posting earnings that beat analyst expectations and raising full-year guidance, while broader market sentiment improved on geopolitical optimism and strong corporate earnings across the board.

The headlines establish that Palantir reported earnings results that exceeded analyst forecasts and issued elevated full-year guidance on August 4, 2026. Multiple sources explicitly tie the stock's 29% gain to this "stellar earnings performance" and "highly optimistic outlook." The move also occurred within a broader market rally—the S&P 500 and Dow hit record highs—driven partly by easing geopolitical tensions around the Strait of Hormuz and general strength in corporate earnings. One analyst comment notes that Palantir's results, alongside Caterpillar's, signal that "AI spending is real and happening," suggesting investor confidence in the company's execution. A secondary effect mentioned is short-seller losses of roughly $3 billion, which may have amplified the move through covering but was a consequence rather than the original catalyst.

MOVE

Movano Inc.Technology

$13.74+$3.22

+28.2%

NASDAQ · Mkt cap $11 M

Corvex (ticker MOVE) announced a multi-year agreement to provide NVIDIA Blackwell GPU infrastructure to a leading AI company, funded through debt and customer prepayments rather than equity dilution, driving a 28% rally on positive news for its AI computing business.

The headlines establish that Corvex signed a multi-year contract to supply NVIDIA Blackwell GPU clusters to an unnamed major customer, with full deployment completed in 2026. The company structured the deal to avoid shareholder dilution by using debt financing, customer prepayments, and existing cash. This is material for an AI infrastructure provider because it demonstrates (1) proof of commercial demand for its GPU services, (2) revenue visibility through a multi-year commitment, and (3) capital discipline in avoiding dilution. The 28% single-day gain reflects investor relief on both the business win and the financing approach. The exact customer identity was not disclosed, which is a minor limitation, but the expansion of an existing relationship with a "leading AI company" suggests established credibility and repeatability of the business model.

ERNA

Eterna Therapeutics Inc.Healthcare

$4.41+$0.97

+28.2%

NASDAQ · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 28.20% gain likely reflects a delayed market reaction to prior news, technical/momentum trading, or an undetected announcement in other channels.

The absence of any Yahoo Finance headlines in the 48-hour window makes it impossible to attribute this move to a specific corporate event like earnings, FDA approval, partnership, or guidance. For a biotech company like Eterna Therapeutics, typical catalysts include clinical trial data, regulatory decisions, financing announcements, or leadership changes. The magnitude of the move—ranking 25th largest gainer of the day—suggests something material occurred, but without headline evidence it may have been announced through other channels (company press release not yet syndicated, social media, or insider discussion), or the move could reflect accumulated momentum or short covering rather than a new catalyst. The stock's price level and sector volatility are also consistent with speculative trading in smaller-cap therapeutics.

APPS

Digital Turbine IncTechnology

$9.50+$2.55

+28.0%

NASDAQ · Mkt cap $1.3 B

Digital Turbine reported strong Q1 fiscal 2027 results and raised full-year guidance on August 4, driving a 28% single-day gain that ranks it the 26th biggest gainer on NASDAQ.

Digital Turbine announced fiscal first quarter results for the period ended June 30, 2026, and simultaneously raised full-year guidance. The timing of this earnings release and forward guidance raise on the snapshot date directly aligns with the large intraday move. Earnings beats combined with raised guidance typically trigger strong investor sentiment, particularly in growth-oriented technology stocks where forward outlook carries significant weight for valuation. The company operates in mobile advertising and app distribution, a sector sensitive to advertising spending trends and user engagement metrics. The magnitude of the move (28%) suggests the results exceeded consensus expectations materially or the guidance raise was substantial enough to reset growth expectations upward for the fiscal year. The SpaceX earnings headline appears unrelated to APPS fundamentals and likely was included in the news feed by coincidence rather than as a causal factor.

ORIC

ORIC Pharmaceuticals IncHealthcare

$13.52+$2.94

+27.8%

NASDAQ · Mkt cap $1.3 B

ORIC Pharmaceuticals announced initiation of a Phase 3 trial for its prostate cancer candidate with a Bayer partnership on August 3rd, triggering a 27.79% gain likely driven by validation of clinical progress and a major pharma collaboration.

The company reported second quarter 2026 financial results alongside two material operational updates: the launch of the Himalayas-1 global Phase 3 trial in metastatic castration-resistant prostate cancer (mCRPC) and a clinical trial collaboration plus supply agreement with Bayer to provide darolutamide for that trial. For a clinical-stage biotech company, advancement to Phase 3 in a disease area with significant market potential represents a critical inflection point. The Bayer partnership carries particular weight because it signals external validation of the compound's promise and potentially de-risks manufacturing and distribution logistics. The timing of results and updates on August 3rd evening aligns precisely with the August 4th trading activity. No negative guidance or operational concerns are mentioned in the headline summary provided.

ADGM

Adagio Medical Holdings, Inc Common StockHealthcare

$0.81+$0.15

+27.3%

NASDAQ · Mkt cap $14 M

Adagio Medical announced it treated its first patient with a next-generation faster, single-freeze ULTA ablation system on August 3, triggering a 27.3% stock surge on clinical progress in its core cardiac arrhythmia treatment technology.

The headline documents a clinical milestone: successful first-patient treatment using Adagio's next-generation ULTA (Ultra-Low Temperature Ablation) system with improved speed and procedural efficiency. For a medical device company focused on catheter ablation, first-patient-treated announcements in a next-generation product line typically signal de-risking of the technology and progress toward commercialization. The stock's strong single-day response reflects investor relief and optimism about product advancement. However, the full impact remains uncertain without details on patient outcomes, timeline to regulatory clearance, or commercial launch expectations, which the truncated headline does not provide.

ZBRA

Zebra Technologies CorpTechnology

$369.29+$77.47

+26.5%

NASDAQ · Mkt cap $16 B

Zebra Technologies beat Q2 earnings estimates by nearly $2 per share, raised full-year 2026 guidance by 13%, and reported record results driven by broad-based sales growth and strong demand for automation and AI solutions, triggering a +26.55% stock surge.

The headlines establish a clear earnings catalyst. Zebra reported record second-quarter results with sales of $1.56 billion, up 20.4% year-over-year, and delivered a +45.98% earnings surprise versus Wall Street's consensus expectation of $3.38 EPS. Management raised full-year guidance materially, and multiple sources highlight strong demand across the company's major segments and regions, with automation and AI solutions driving growth. One headline notes that a memory chip shortage is constraining upside potential in 2026, but this appears positioned as a "best problem" reflecting robust underlying demand rather than a negative. The +26.55% move is consistent with a stock that delivered both an earnings beat and a significant guidance raise on the same day, in a sector environment where tech stocks are broadly rallying following strong earnings across the automation and AI landscape.

BJDX

Bluejay Diagnostics, Inc.Healthcare

$1.03+$0.25

+26.3%

NASDAQ · Mkt cap $1.0 M

No news headlines were available in the last 48 hours, so the 26% gain is likely driven by technical factors, short covering, or undisclosed material information not yet captured in the RSS feed.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for BJDX's strong 26% move on August 4, 2026. Bluejay Diagnostics is a clinical diagnostics company, and moves of this magnitude in micro-cap or small-cap biotech stocks often correlate with clinical trial results, FDA feedback, partnership announcements, or earnings surprises. Without confirmed headlines, the driver could be a delayed announcement not yet indexed by Yahoo Finance, short squeeze activity on a thinly traded stock, sector rotation, or forward-looking institutional positioning ahead of an expected event. The rank as the 30th biggest gainer suggests this was a meaningful mover relative to the broader market, but without news evidence the underlying cause remains speculative.

JELD

JELD-WEN Holding IncIndustrials

$1.79+$0.37

+25.7%

NYSE · Mkt cap $177 M

JELD-WEN reported Q2 2026 earnings with 8% adjusted EBITDA growth and raised full-year guidance, beating expectations and triggering a 25.7% stock jump as of August 4th.

The headlines establish that JELD-WEN announced Q2 2026 results on August 3rd showing better-than-expected performance. Revenue was essentially flat year-over-year at approximately $818 million, but the company posted 8% adjusted EBITDA growth—notable as the first EBITDA expansion in ten years—and raised its full-year revenue guidance to $3.15 billion. The earnings beat combined with positive forward guidance, despite acknowledged cost headwinds and tariff pressures affecting the building products sector, drove investor confidence. The stock initially jumped 19.3% on August 3rd following the announcement and has continued to gain through August 4th, reaching the 25.7% intraday jump shown in this snapshot. This is a straightforward earnings-driven rally on margin expansion and improved outlook.

PONOR

Pono Capital Four, Inc. Rights

$0.25+$0.05

+24.9%

NASDAQ

No headlines reported in the last 48 hours; the 24.88% gain in PONOR rights is likely driven by technical factors, retail activity in micro-cap securities, or unreported corporate developments.

PONOR (Pono Capital Four Rights) experienced a substantial single-day gain with no corresponding news coverage in the provided headline sources. Rights offerings are relatively illiquid securities that can exhibit outsized percentage moves on modest absolute volume shifts or technical buying pressure. Possible explanations include: one, a positive development in the parent SPAC or merger negotiations that has not yet appeared in major news feeds; two, technical chart breakout or short covering in a thinly-traded micro-cap; three, retail momentum or social media discussion driving demand for the rights themselves. Without confirming headlines, the specific catalyst remains opaque. This class of security (rights) typically lacks broad analyst coverage and news dissemination compared to common shares.

UFPT

UFP Technologies IncHealthcare

$335.10+$65.57

+24.3%

NASDAQ · Mkt cap $2.2 B

UFP Technologies reported record Q2 2026 earnings that beat Wall Street expectations on both revenue and EPS, with 15.1% sales growth and 16.8% EPS growth, triggering the 24% rally as a strong earnings beat catalyst.

The headlines establish a clear and consistent narrative: UFP Technologies delivered Q2 results that exceeded analyst expectations across multiple metrics. Revenue came in at $173.96–$174 million with 15.1% year-over-year growth, net income reached $20.85 million, and adjusted EPS grew 16.8%, all ahead of consensus. Multiple sources describe earnings surprises of 16.34% on earnings and 8.85% on revenue. The stock's 24% gain ranks it among the day's biggest gainers and aligns directly with the magnitude of the beat and the company's track record of sustained double-digit growth in its medical device and contract manufacturing segment. This is a textbook post-earnings rally driven by a company exceeding expectations and maintaining strong momentum.

ABTS

Abits Group IncFinancial Services

$1.28+$0.25

+24.2%

NASDAQ · Mkt cap $4.1 M

No news headlines were available in the last 48 hours for ABTS, so the 24% gain on August 4, 2026 cannot be directly attributed to a specific corporate announcement or event from the provided information.

The absence of recent news headlines makes it difficult to pinpoint a definitive cause for the sharp 24% intraday move. Micro-cap and penny-stock securities like ABTS, trading near $1.28, are particularly susceptible to several categories of catalysts that may not immediately surface in mainstream financial RSS feeds. These could include delayed press releases or investor relations announcements not yet picked up by Yahoo Finance, technical or momentum-driven moves from short covering or algorithmic trading, insider activity or institutional accumulation, sector rotation into small-cap growth names, or speculative positioning ahead of an earnings date or corporate action. Without access to the company's website, SEC filings, or direct press releases, any specific attribution would be speculation rather than analysis.

DBGI

Digital Brands Group, Inc.Consumer Cyclical

$22.09+$4.22

+23.6%

NASDAQ · Mkt cap $6.8 M

Digital Brands Group announced on August 3 that it is undertaking a strategic review and has retained financial advisors to explore alternatives including potential sale or merger, sparking a 23.6% jump as investors bet on a value-creation transaction.

The company's August 3 announcement of a formal strategic review with retained financial advisors directly preceded the 23.6% gain on August 4. The headlines establish that Digital Brands Group is explicitly considering strategic alternatives to maximize shareholder value, including a potential sale or merger. This type of announcement typically triggers immediate investor enthusiasm because it signals management recognition that the current business may be worth more to a buyer than trading at its current market price, or that a merger could unlock hidden value. The market's interpretation—reflected in the substantial single-day gain—suggests investors view the review as credible and believe there is meaningful upside potential if a transaction occurs. No earnings report, guidance, or other competing catalyst is mentioned in the provided news.

LESL

Leslie''s IncConsumer Cyclical

$1.32+$0.25

+23.4%

NASDAQ · Mkt cap $6.1 M

No headlines were published about LESL in the last 48 hours, so the 23.36% jump likely reflects technical trading activity, market rumors, or a delayed earnings or business announcement not yet captured in the news feed.

Leslie's Inc operates in the pool supplies and maintenance business, which is typically defensive and stable but not prone to explosive single-day rallies without concrete news. The absence of any headlines in the last 48 hours suggests either a significant announcement or company filing has not yet been picked up by major news aggregators, or the move is driven by technical factors such as short covering, options expiration, or retail trading flows. Pool supply retailers occasionally see spikes around seasonal demand shifts or cost management announcements, but without access to recent earnings reports, guidance updates, or insider transactions, identifying the precise catalyst is impossible. The timing and magnitude of this gain (23.36% to place it 36th largest gainer) suggests something material occurred, but the news blackout prevents confirmation of what that driver actually was.

AMRC

Ameresco IncIndustrials

$27.96+$5.28

+23.3%

NYSE · Mkt cap $1.2 B

Ameresco surged 23.26% on August 4th following strong Q2 earnings reported on August 3rd, featuring a record $1.8 billion in new project awards, 9% revenue growth, and raised full-year EPS guidance.

The stock's jump is directly attributable to Ameresco's Q2 2026 earnings release on August 3rd. The company reported revenue of $515.5 million, beating Wall Street expectations by 14.9%, with year-over-year growth of 9.1%. Most notably, the company announced record new project awards of $1.8 billion, driven substantially by data center-related power infrastructure projects. Additionally, the company raised its non-GAAP EPS guidance for the full year and highlighted 21% growth in energy asset revenue. These results appear to have reversed market sentiment that had previously characterized the stock as "circling the drain." The combination of a revenue beat, record bookings, margin expansion in key segments, and raised guidance provided concrete reasons for institutional and retail investors to reprice the stock upward.

INSP

Inspire Medical Systems IncHealthcare

$64.21+$12.06

+23.1%

NYSE · Mkt cap $1.8 B

Inspire Medical beat Q2 earnings and revenue estimates and raised full-year 2026 guidance, driving the 23% stock jump, despite reporting a 7.6% year-over-year revenue decline from reimbursement disruptions.

The earnings call on August 3-4 disclosed that Inspire Medical delivered earnings and revenue surprises relative to Wall Street consensus, with earnings beating by 163.64% and revenue by 2.95% for the quarter ended June 2026. Although Q2 revenue of $200.6 million represented a 7.6% year-over-year decline due to ongoing coding and reimbursement pressures, the company offset investor concerns by raising its full-year 2026 outlook. The company also announced Project Horizon, described as a strategic initiative to drive future growth, and appointed AtriCure CEO Michael Carrel to its board. The combination of better-than-expected profitability, an upgraded forward guidance, and a forward-looking growth project appears to have convinced the market that near-term headwinds are temporary and that long-term value creation remains intact.

Gartner IncTechnology

$185.91+$34.41

+22.7%

NYSE · Mkt cap $12 B

Gartner reported Q2 earnings that beat EPS estimates by 15.92%, raised full-year 2026 guidance despite flat year-over-year revenues, and posted stronger margins with accelerating contract value growth, driving the 22.71% stock surge.

Gartner released Q2 2026 results on August 4, 2026 that significantly exceeded profit expectations and prompted management to raise both EPS and cash-flow guidance for the full year. While reported revenues of $1.68 billion were essentially flat year-over-year and slightly below some expectations, the market response focused overwhelmingly on non-GAAP EPS of $4.37, which was 17.1% above consensus, and the upgraded 2026 outlook. Headlines consistently note that client engagement improved, contract value growth reaccelerated for a second consecutive quarter, and margins expanded despite softer revenues. The divergence between lower-than-expected top-line growth and strong bottom-line performance with raised guidance appears to have been the key driver, as multiple sources explicitly note analysts did not penalize the revenue miss. The strength in profitability metrics and forward guidance outweighed the near-flat sales growth.

LPSN

LivePerson IncTechnology

$2.20+$0.41

+22.6%

NASDAQ · Mkt cap $36 M

LivePerson stock surged 22.56% following a reminder of an investor town hall scheduled for August 5, suggesting market anticipation of material announcements or guidance from management that may be disclosed at the event.

The sole headline provided is a routine reminder about an upcoming investor town hall and Q&A webcast on August 5, 2026. The announcement itself contains no new financial data, product launches, partnerships, or forward guidance. However, the timing of a significant 22.56% single-day rally coinciding with a stockholder notification of an imminent town hall suggests market participants are expecting management to announce material information at the event. This is reasonable inference rather than established fact. The stock may be responding to anticipation of positive news (restructuring, new contracts, profitability milestones, strategic pivots) that insiders or analysts believe will be discussed. Alternatively, short covering or technical momentum in a small-cap software stock could contribute, but the town hall timing is suggestive of event-driven catalyst expectations.

TELA

Tela Bio IncHealthcare

$0.91+$0.17

+22.5%

NASDAQ · Mkt cap $29 M

TELA Bio announced the appointment of Heather Getz as Chief Executive Officer and Director on August 4, 2026, likely triggering the +22.53% gain as investors reacted positively to the leadership change.

The headline reveals that TELA Bio appointed a new CEO and board director on the exact date of the stock's surge, which is the most straightforward explanation for the timing and magnitude of the move. Leadership transitions at small-cap medical device companies often attract investor attention, particularly if the new executive brings relevant experience or if the market had concerns about prior management. Without additional context about Getz's background, track record, or the circumstances of the prior CEO's departure, it is unclear whether the market is rewarding specific strategic expectations or simply expressing relief at a governance change. The stock's rank as the 41st biggest gainer suggests the move reflects genuine buying interest rather than typical daily noise, which aligns with a material corporate event.

RYM

Agrify CorporationConsumer Defensive

$25.30+$4.65

+22.5%

BWEN

Broadwind Energy IncIndustrials

$4.97+$0.90

+22.1%

NASDAQ · Mkt cap $115 M

No news headlines were found in the last 48 hours, so the 22% gain on BWEN likely reflects technical trading, delayed market reaction to an earlier announcement, or sector-wide momentum in renewable energy.

Broadwind Energy is a wind energy component and service provider, a sector that can be volatile and responsive to policy shifts, commodity prices, and order flow. The absence of any reported news in the last 48 hours is noteworthy given the magnitude of the move, suggesting either a delayed market reaction to information released earlier than the headline window, technical or algorithmic buying following a breakdown of resistance, renewed interest in clean energy stocks tied to macroeconomic or political developments not yet reflected in the RSS feed, or short covering if the stock had accumulated significant short interest. Without access to intraday volume or broader sector performance data for that date, it is difficult to distinguish among these scenarios. The rank as the 43rd biggest gainer suggests broad market participation rather than isolated insider activity.

COPL.WT

Copley Acquisition Corp WT

$0.10+$0.02

+22.0%

PSIX

Power Solutions International, Inc.Industrials

$34.93+$6.25

+21.8%

NASDAQ · Mkt cap $934 M

No news headlines were found in the last 48 hours, so the cause of the 21.79% gain cannot be determined from available reporting. The jump may reflect earnings, contract wins, analyst upgrades, or technical factors.

Power Solutions International (PSIX) gained 21.79% on August 4, 2026, ranking 45th among daily gainers, yet no news articles appeared in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect between price action and headline availability is noteworthy. The move could reflect several categories of catalyst typical for industrial and power generation equipment manufacturers: a quarterly earnings beat or upside guidance revision released after market close on August 3, announcement of a major OEM contract or supply agreement, an analyst upgrade or price target increase from a major firm, positive sector developments affecting demand for power solutions, or technical factors such as short covering or options-related buying. Without corresponding headlines, the precise trigger remains speculative, though for a mid-cap industrial stock like PSIX, earnings surprises and contract announcements are the most common drivers of moves of this magnitude.

EVGN

Evogene LtdHealthcare

$0.65+$0.11

+21.4%

NASDAQ · Mkt cap $9.5 M

No news headlines were available in the last 48 hours to explain Evogene's 21.44% jump to $0.65, so the catalyst remains unclear from public announcements.

Evogene Ltd is a computational biology and genetics company with a history of volatile trading, particularly common for small-cap biotech and agtech firms trading at sub-dollar prices. The absence of news in the provided feed does not rule out genuine catalysts—earnings results, clinical or regulatory updates, partnership announcements, or analyst upgrades may have been released but are simply not captured in this snapshot. Alternatively, the move could reflect technical factors such as short covering, options-related positioning, or general market sentiment shifts toward small-cap life sciences names. Given the stock's low price point and likely thin float, even modest volume can produce outsized percentage moves. Without access to the actual news, regulatory filings, or trading volume data, identifying the specific driver is not possible from the evidence at hand.

KBSX

FST Corp. Ordinary SharesConsumer Cyclical

$1.13+$0.20

+21.2%

NASDAQ · Mkt cap $45 M

FST Corp. announced its KBS Putter Shafts were selected as the stock offering across TaylorMade Golf's new Spider Tour and Spider ZT Max Putter families on August 4, likely driving the 21.23% gain.

The headline directly references a product placement win with TaylorMade Golf, a major equipment manufacturer. FST Corp. manufactures golf shafts, so securing a stock offering position across two new putter families from a prominent brand represents meaningful commercial validation and potential revenue contribution. The timing of the announcement (same day as the move) and the prominence of TaylorMade in golf equipment make this a concrete business development catalyst. For a small-cap stock trading at $1.13, a tangible partnership or expanded distribution deal can justify a 20%+ single-day move, particularly if investors previously underestimated the company's competitive positioning or if the deal's scope was larger than anticipated. The rank as the 47th biggest gainer suggests this was market-wide attention rather than isolated sentiment.

BBGI

Beasley Broadcast Group IncCommunication Services

$25.76+$4.48

+21.1%

NASDAQ · Mkt cap $37 M

BBGI jumped 21% likely due to short covering, technical strength, or market sentiment ahead of the Q2 2026 earnings report scheduled for August 10. The announcement itself was made August 3 after hours, so timing alone does not explain the August 4 rally.

The only news in the past 48 hours is a routine earnings announcement on August 3 stating that Q2 2026 results will be released August 10 before market open. This is a procedural disclosure, not new financial data or guidance, and does not typically trigger a 21% single-day move. The timing mismatch suggests the rally on August 4 was either a delayed reaction to the earnings calendar notice, short-covering by investors anticipating volatility ahead of results, technical momentum in a smaller-cap stock, or an unrelated market catalyst not captured in the provided headlines. Broadcast radio stocks can be volatile on relatively light volume, making them susceptible to momentum-driven moves. Without additional context on short interest, options activity, or broader sector news, the precise trigger remains unclear.

LIFE

aTyr Pharma IncFinancial Services

$27.62+$4.79

+21.0%

NASDAQ · Mkt cap $3.6 B

Ethos Technologies (ticker LIFE) reported Q2 2026 earnings with 113% revenue growth to $190 million, exceeding typical growth expectations and triggering a 21% single-day gain.

The company delivered strong second-quarter fiscal 2026 financial results with revenue surging 113% year-over-year to approximately $190 million. Growth was broad-based, with direct-to-consumer revenue up 131% and third-party channel revenue up 90%. The earnings call highlights mention a Rule of 40 score of 132, indicating the company is balancing exceptional growth with profitability or efficiency metrics that investors reward. The board also authorized a share repurchase program, which typically signals management confidence in the stock's valuation. The magnitude of the revenue acceleration and the combination of growth metrics with capital allocation announcement appear sufficient to justify the 21% rally. Note that the ticker symbol discrepancy in the news (Ethos Technologies versus aTyr Pharma Inc as stated in the prompt) creates minor ambiguity, but the earnings narrative is consistent and substantive.

GCTS.WT

GCT Semiconductor Holding, Inc. WT

$0.40+$0.07

+20.3%

Biggest Losers

Tue, Aug 4, 2026 50

NXTT

Next Technology Holding Inc.Technology

$0.11−$0.31

-73.4%

NASDAQ · Mkt cap $9.8 M

No news headlines were available in the last 48 hours to explain the 73.40% crash in NXTT, making the direct cause unknown; the move may reflect a delayed market reaction, technical breakdown, or negative development not yet captured by major news feeds.

NXTT experienced a severe single-day decline to $0.11 with no corresponding headlines in the recent news feed. This disconnect between magnitude of move and public information availability is notable. For a micro-cap stock trading at this price level, several categories of catalyst are plausible: corporate actions such as reverse splits, dilutive financing announcements, or delisting warnings often drive sharp moves in penny stocks; operational announcements (missed milestones, executive departures, regulatory issues) that may circulate on lower-tier sources before reaching major news aggregators; or technical capitulation in a stock that may have been in downtrend. Without access to company filings, press releases, or lower-tier financial news sources, the specific trigger remains undetermined.

RAIN

Rain Therapeutics Inc.Industrials

$1.16−$2.64

-68.4%

NASDAQ · Mkt cap $10 M

The single recent headline describes a fireside chat event but contains no material news, earnings, guidance, or adverse information that would explain a 68% one-day collapse; the catalyst for this severe decline is not identified in the available news.

The only headline provided is a neutral announcement of a fireside chat between Rain's CEO and IPO Edge on August 3, which is a routine investor relations event with no disclosed substance or market-moving announcements. This type of content rarely triggers stock declines of this magnitude. A 68% one-day drop in a publicly traded company typically stems from material adverse events such as failed clinical trials, missed earnings, negative guidance revision, regulatory setbacks, or major shareholder dilution. Without such news in the provided headlines, the specific catalyst remains unknown. This could reflect a delayed market reaction to an earlier announcement not captured here, technical selling or margin calls, a short squeeze reversal, or breaking news not yet reflected in the RSS feed provided.

ALCE

Alternus Clean Energy, Inc.Utilities

$0.06−$0.05

-45.5%

NASDAQ · Mkt cap $43 K

No news headlines were published in the last 48 hours for ALCE, so the 45.45% drop cannot be attributed to a specific announced event; the decline may reflect technical selling, delayed market reaction to prior news, or broader sector pressure on small-cap clean energy stocks.

Without recent news coverage, there is no headline-grounded explanation for the sharp intraday move. ALCE is a micro-cap clean energy stock trading at $0.06, which typically exhibits high volatility and thin liquidity. The 45.45% single-day loss in a stock of this size and sector could reflect several non-headline-driven scenarios: technical selling or stop-loss cascades triggered by a breach of support levels, delayed market reaction to an older announcement that was not picked up by Yahoo Finance's 48-hour window, short-covering reversals, or sector-wide pressure on renewable energy equities. Without access to intraday volume, bid-ask spreads, or prior-week context, any specific catalyst remains speculative. The absence of news is itself notable and suggests either that the move is technically driven or that a catalyst exists outside the news feeds provided.

FWACW

Futurewave Acquisition Corporation Warrants

$0.03−$0.02

-40.0%

AHCO

AdaptHealth CorpHealthcare

$6.71−$4.12

-38.0%

NASDAQ · Mkt cap $806 M

AdaptHealth reported Q2 earnings that missed revenue expectations, posted higher-than-expected costs on a West Coast contract, and sharply lowered full-year profitability guidance, triggering a 38% stock decline.

The earnings headlines establish a clear narrative of operational disappointment. AdaptHealth's Q2 2026 revenue of $740.3 million fell 7.5% year-over-year and missed analyst estimates. More critically, the company cited higher-than-expected costs in its West Coast capitated contract as a major headwind and responded by significantly reducing full-year profitability guidance despite reporting revenue growth in continuing operations. The company also navigated a diabetes divestiture and Humana expansion during the quarter. The magnitude of the stock decline (38% same-day) reflects the severity of the guidance cut and the apparent surprise nature of the cost overruns. While the broader market advanced on geopolitical optimism and healthcare stocks were modestly softer as a sector, AHCO's decline far exceeds sector headwinds, indicating company-specific negative catalysts dominated the move.

BETR

Better Home & Finance Holding Co.Financial Services

$17.35−$10.03

-36.6%

NASDAQ · Mkt cap $248 M

Better Home & Finance announced a CEO transition to interim leadership and announced cost-cutting measures of $45M+, with second quarter earnings due August 6; the leadership change combined with the timing of results likely triggered the sharp 37% drop.

The headline evidence points to two material developments: (1) appointment of Daniel Lewis as interim CEO on August 3, signaling leadership instability or a planned transition, and (2) announcement of annualized cost cuts exceeding $45 million by year-end, which typically suggests operational challenges or margin pressure requiring significant restructuring. The company also issued a corrected earnings announcement on August 4, indicating administrative issues with their disclosure process. Interim CEO appointments often concern investors due to uncertainty about strategic direction and execution. The magnitude of announced cost cuts is substantial relative to a company trading at this market cap and hints at profitability or cash flow stress. Earnings results on August 6 are imminent, creating additional uncertainty. Investors appear to be pricing in negative expectations ahead of those results and interpreting the leadership change as a signal of distress rather than planned succession.

GYGY

Game Your Game, Inc.Technology

$3.98−$2.06

-34.0%

NASDAQ · Mkt cap $25 M

No news headlines were available in the last 48 hours for GYGY, so the 34% single-day decline cannot be directly attributed to a public announcement; the drop likely reflects either a delayed market reaction to an earlier event, technical selling pressure, or an undisclosed corporate action.

Despite GYGY ranking as the seventh-largest loser on August 4, 2026, no recent news headlines appear in the data provided. This absence of news does not rule out causation but prevents pinpointing a specific catalyst. For a gaming or entertainment stock of this market cap, major drivers of sharp declines typically include disappointing earnings or revenue guidance, executive departures, loss of a major licensing or partnership agreement, regulatory action, or technical capitulation following a period of weakness. The magnitude of the move—nearly 34% in a single day—suggests either an event with material negative implications or accumulated selling pressure reaching a breaking point. Without access to intraday commentary, SEC filings, or company-issued press releases, the precise cause remains unknown.

ENSC

Ensysce Biosciences, Inc.Healthcare

$0.39−$0.17

-30.3%

NASDAQ · Mkt cap $7.5 M

No news headlines were published in the last 48 hours to explain the 30.32% drop in ENSC stock on August 4, 2026, so the cause remains unclear without access to intraday announcements or broader market events.

The absence of any Yahoo Finance headlines in the last 48 hours makes it impossible to identify a specific news catalyst for this significant single-day decline. ENSC is a small-cap biotech company, and stocks in this sector can experience sharp moves on several types of events: clinical trial results or setbacks, FDA decisions or delays, financing announcements (dilutive offerings are common in cash-constrained biotech), regulatory warnings, or shifts in market risk appetite affecting speculative positions. The stock's low absolute price of $0.39 suggests limited liquidity and volatility typical of micro-cap or distressed biotech names, where moves can be sharp and sometimes disconnected from mainstream financial media coverage. Without news headlines or knowledge of intraday announcements, the specific trigger cannot be determined from available information.

THRY

Thryv Holdings, Inc.Technology

$2.97−$1.28

-30.0%

NASDAQ · Mkt cap $93 M

Thryv announced Q2 earnings that missed on EPS (3,900% negative surprise) despite beating revenue, and the stock crashed 30% despite simultaneous positive news including major partnerships with Wix and Ooma and launch of a new AI growth platform.

On August 4, 2026, Thryv reported Q2 results showing a substantial earnings miss of 3,900% negative surprise while topping revenue estimates by 3.95%. The same day brought multiple positive announcements including strategic partnerships with Wix and Ooma, plus the launch of its AI-native Growth Platform, which management characterized as a significant SaaS transformation milestone. The 30% single-day decline suggests the earnings miss, particularly the magnitude of the EPS shortfall, overwhelmed investor sentiment despite the strategic initiatives and partnership announcements. The company is also hosting an investor product demo on August 6 to showcase the new platform. The disconnect between operational news (partnerships, platform launch) and financial results (large loss) indicates the market is currently punishing profitability over growth narrative.

REZI

Resideo Technologies IncIndustrials

$26.15−$10.11

-27.9%

NYSE · Mkt cap $3.0 B

Resideo completed a spin-off of ADI Global Distribution on August 4, 2026, which typically causes the parent company stock to decline as shareholders receive shares in the new entity and the market reprices the remaining business.

The headlines confirm that Resideo Technologies completed the spin-off of ADI Global Distribution on August 4, 2026, with ADI beginning trading on the NYSE under ticker ADIG. Spin-offs mechanically reduce the market capitalization of the parent company as a portion of its assets and operations are separated into an independent entity. Shareholders of REZI receive shares of the newly spun ADI as a dividend, but the combined market value of both stocks post-spin often differs from the pre-spin parent valuation due to separation costs, different growth profiles, market repricing, and loss of diversification. The 27.88% decline on the spin-off announcement date is substantial but consistent with the market repricing Resideo as a pure-play control and sensing solutions manufacturer rather than a diversified conglomerate including ADI's distribution business. The third news item about "Wall Street's Favorite Stocks with Warning Signs" is dated the same day but appears to be generic market commentary unrelated to REZI's specific event.

TYGO

Tigo Energy IncTechnology

$2.06−$0.51

-26.0%

NASDAQ · Mkt cap $88 M

Tigo Energy reported Q2 2026 earnings on August 4, triggering a 26% stock decline, suggesting the results missed expectations or included negative guidance despite a concurrent positive installer loyalty announcement.

The timing of the 26% drop aligns precisely with Tigo's Q2 2026 earnings release on August 4. The headline references "unaudited financial results" but provides no detail on revenue, margins, profitability, or forward guidance. A drop of this magnitude in a solar technology company typically reflects either significantly missed revenue or profit targets, disappointing guidance relative to consensus, deteriorating gross margins, or material cash burn concerns. The August 3 news about recognizing Stanton Solar as a top-tier loyalty installer appears positive operationally but carries no revenue quantification and appears insufficient to offset earnings concerns. Without access to the actual earnings report details, the most likely explanation is that Q2 results disappointed the market in a fundamental way. Solar equipment and software companies are sensitive to end-market demand signals, margins, and cash position visibility.

FUSE

Fusion Acquisition CorpTechnology

$1.02−$0.35

-25.5%

NYSE · Mkt cap $24 M

FUSE fell 25.55% likely due to dilution concerns triggered by Fusemachines' $10.66 million convertible note and warrant issuance at $4.20 per share, signaling potential shareholder dilution from a SPAC-backed entity.

The headline announces a $10.66 million investment by Meteora Capital into Fusemachines (the operating company within the FUSE SPAC structure) consisting of a $2.5 million convertible note and cash-exercise warrants, both at a fixed $4.20 conversion and exercise price with no reset provisions. This is a material dilution event for existing shareholders. SPAC investors are particularly sensitive to post-merger dilution, especially when new capital is raised at per-share prices that may be below current market expectations or create overhang from warrant exercises. The magnitude of the decline (rank 12 biggest loser) suggests this was a significant negative catalyst. The fixed pricing without resets indicates downward pressure risk if the stock declines further, which could have triggered selling as investors anticipate additional dilution ahead.

SMTK

SmartKem, Inc.Technology

$0.16−$0.05

-25.1%

NASDAQ · Mkt cap $2.2 M

SmartKem announced a merger with Ferrox Critical Minerals on August 3rd, valued at $125 million in an all-stock deal, likely causing shareholder dilution concerns and the 25% drop in SMTK stock price.

SmartKem announced it will merge with Ferrox Critical Minerals in an all-stock transaction that values Ferrox at $125 million. The company framed this as strategically extending its materials platform beyond electronic materials into critical minerals to create an integrated electronics company. However, all-stock mergers typically dilute existing shareholders significantly, and the $125 million valuation of the acquired company relative to SmartKem's current market capitalization (roughly $30 million at current price) represents substantial dilution. Additionally, reverse merger or integration announcements in microcap stocks often trigger sell-offs as investors reassess capital structure and future equity ownership percentages. The market's negative reaction suggests investors view the dilution and integration risks as outweighing the strategic benefits of the combination.

MGN

Megan Holdings LimitedIndustrials

$0.15−$0.05

-24.8%

NASDAQ · Mkt cap $3.7 M

No news headlines were found in the last 48 hours for MGN, so the 24.76% drop likely reflects a delayed market reaction to older news, technical selling, or micro-cap volatility typical of penny stocks trading at $0.15.

The absence of recent headlines makes it impossible to pinpoint a specific catalyst for today's sharp decline. MGN is a micro-cap stock trading at a very low price, and such securities are prone to large percentage swings on modest volume, technical breakdowns, or delayed digestion of older announcements. Possible explanations—though unsupported by the evidence provided—include: (1) a significant corporate announcement, earnings miss, or adverse event that occurred more than 48 hours ago and is only now fully reflected in the stock price, or (2) purely technical or sentiment-driven selling common in illiquid penny stocks. Without access to older news or internal company developments, we cannot distinguish between these scenarios. The rank as the 14th biggest loser suggests the move is material on a daily basis but does not clarify its origin.

TGHL

The GrowHub Limited Class A Ordinary SharesTechnology

$0.91−$0.29

-24.5%

NASDAQ · Mkt cap $17 M

TGHL fell 24.46% with no news reported in the last 48 hours, making the specific catalyst unclear; the decline may reflect sector pressure, technical selling, delayed news absorption, or undisclosed company-specific developments.

No recent headlines were found in the last 48 hours to explain this sharp 24 percent single-day decline. For a small-cap stock like TGHL trading near a dollar, typical catalysts for such moves include missed earnings or negative guidance, insider selling or dilutive financing announcements, sector-wide pressure in biotech or cannabis (if applicable to this company), technical breakdown below key support levels, or negative analyst commentary that may not yet be reflected in Yahoo Finance headlines. Without access to the company's sector classification, recent SEC filings, or broader market context for August 4 2026, it is not possible to definitively attribute this move. The absence of reported news within 48 hours does not rule out an announcement made earlier that day or pre-market; it only means the headline feed captured nothing.

DFNS

Defense Industries International IncIndustrials

$47.05−$14.28

-23.3%

NYSE · Mkt cap $27 M

DFNS dropped 23.28% despite T3 Defense (the company's subsidiary) announcing a new Israeli defense contract with $2M scaling potential on August 4th, suggesting the market's negative reaction was driven by factors other than the headline news itself.

The timing is unusual: a positive contract announcement arrived the same day as a severe 23% decline, which raises questions about causality. The headline describes a purchase order from an Israeli defense contractor for infrared electro-optical simulation, with initial orders and $2M upside potential—normally a constructive development for a defense technology company. However, the sharp drop suggests either the market viewed the contract as insufficient to move the needle given company size or valuation, or that a separate negative catalyst (earnings miss, guidance reduction, insider selling, sector rotation, or broader defense sector weakness) overshadowed the news. Without access to the full press release, earnings results, or broader market context on defense stocks that day, the disconnect between positive news and sharp price action cannot be definitively resolved.

FERAR

Fifth Era Acquisition Corp I Rights

$0.23−$0.07

-23.3%

NASDAQ

No news headlines were found in the last 48 hours to explain the 23.27% decline in FERAR, a SPAC rights offering that is inherently volatile and prone to sharp moves on low trading volume without public catalysts.

The absence of any headlines in the past two days makes it impossible to identify a specific news-driven cause for this decline. FERAR is a rights offering tied to a blank-check acquisition vehicle, which are structurally sensitive to sentiment shifts regarding SPAC valuations, merger deal timing, redemption risk, and broader market appetite for speculative equity. Rights offerings typically trade with thin liquidity and can experience outsized percentage swings on modest volume shifts. Possible inference-level explanations include deterioration in investor appetite for SPAC transactions, a broader decline in the underlying target company's prospects (if the merger terms are public), or simply technical selling pressure on a low-float security. Without access to trading volume, short interest data, or SPAC-specific news flows, the actual catalyst remains opaque.

APMCR

AmperCap Acquisition Company Right

$0.10−$0.03

-23.1%

NASDAQ

No news headlines were available in the last 48 hours to explain the 23% drop. APMCR, a SPAC rights offering, likely declined due to typical illiquidity, low trading volume, or technical factors common to low-priced special purpose acquisition company securities.

The absence of any news in the provided headlines makes it impossible to identify a specific catalyst for the decline. However, APMCR is a rights offering associated with a SPAC structure, which typically trades at very low prices and exhibits high volatility relative to trading volume. These securities often experience sharp percentage moves on minimal volume without accompanying news, driven by bid-ask spreads, thin liquidity, or technical selling. The 23% decline on no identifiable news event is consistent with the characteristic behavior of low-priced SPAC-related instruments. A broader market decline on 2026-08-04 or redemption/expiration dynamics tied to the underlying merger timeline could also explain the move, but neither can be confirmed from the evidence provided.

BRKR

Bruker CorpHealthcare

$50.30−$14.07

-21.9%

NASDAQ · Mkt cap $9.1 B

Bruker beat EPS estimates by 29% and returned to organic revenue growth with strong bookings, but missed revenue estimates by 2.2%, triggering a sharp selloff despite otherwise positive fundamentals and maintained guidance.

The headline evidence is mixed and somewhat contradictory. Multiple sources confirm Bruker posted Q2 results on August 4, 2026 with 5.2% organic revenue growth, a 53% EPS jump, and strong demand in biopharma and semiconductor segments. However, the revenue miss versus Wall Street estimates appears to be the primary catalyst for the 21.86% single-day drop. One headline explicitly states the company "missed Wall Street's revenue expectations in Q2" with sales of $838.5 million, and another notes the stock already dropped 11.9% on that news. Despite management maintaining full-year guidance of $3.56 billion and expanding profitability, the initial revenue disappointment and possibly the currency headwinds mentioned in the earnings announcement seem to have overridden the positive EPS surprise and bookings acceleration. The market may also be pricing in disappointment about U.S. academic weakness noted in the headlines.

CTRI

Centuri Holdings IncUtilities

$21.90−$6.00

-21.5%

NYSE · Mkt cap $2.1 B

Centuri posted strong Q2 earnings with 33% revenue growth, beat estimates, and raised full-year guidance, yet the stock fell 21.51%, suggesting the market's positive reaction may have already been priced in or investors are concerned about execution risks despite the headline beats.

The headlines describe a classically bullish earnings event: record revenue, a 33% growth rate, a major data center contract win, beats on both earnings and revenue, and raised full-year guidance. Normally these would drive share price appreciation. However, a 21.5% single-day drop on such news points to one of two dynamics. First, the positive news may have been heavily anticipated and already reflected in the stock price before market open, leaving sellers to dominate after the announcement. Second, despite the headline metrics, investors may have discovered concerns during the earnings call or in forward guidance that offset the near-term strength, such as margin pressure from fuel costs (noted in the headlines), execution risk on the large data center project, or disappointing guidance for quarters beyond the current year. Without access to the full call transcript or analyst commentary, the disconnect between news tone and price action remains unexplained by the evidence provided.

IPEXR

Inflection Point Acquisition Corp. V

$0.51−$0.12

-19.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 19% drop cannot be attributed to a specific announced catalyst; the decline likely reflects either technical selling, broader market conditions, or company-specific developments not yet reported.

Inflection Point Acquisition Corp. V is a blank-check company (SPAC), and the absence of any news in the last 48 hours means the price move cannot be tied to earnings, acquisition announcements, or regulatory events through public reporting. SPACs are particularly sensitive to liquidity conditions, redemption risk, interest rate expectations, and sentiment around their pending or rumored business combinations. A 19% drop on no news is unusual and could indicate insider trading revelations, a failed or withdrawn merger announcement that hasn't yet surfaced in headlines, deteriorating market appetite for blank-check vehicles, or technical selling pressure in a low-liquidity microcap security. Without confirmed reporting, any specific cause remains speculative.

SUGP

SU Group Holdings Limited Ordinary SharesIndustrials

$0.38−$0.09

-18.9%

NASDAQ · Mkt cap $6.9 M

SU Group received a NASDAQ delisting determination on August 3 and announced a 1-for-5 reverse stock split on August 4, triggering an 18.85% single-day drop as investors react to imminent delisting risk and equity dilution concerns.

The stock faced two material headwinds in rapid succession. First, SU Group received a formal delisting determination from NASDAQ staff on August 3, 2026, though the company stated it intends to request a hearing to contest the determination. This delisting threat alone typically crushes stock price as it signals regulatory compliance failure and upcoming loss of exchange listing. Second, on the same day as the price drop, the company announced a 1-for-5 reverse stock split, a move commonly used by struggling companies to artificially raise share price above minimum listing thresholds. Reverse splits often signal financial distress and are frequently viewed negatively by the market as they reduce shareholder equity per share nominally. Together, these announcements create a compelling narrative of a company in regulatory jeopardy attempting a last-resort restructuring, explaining the sharp 18.85% single-day decline.

AACBR

Artius II Acquisition Inc. Rights

$0.13−$0.03

-18.6%

NASDAQ

No news headlines were published in the last 48 hours, so the 18.63% drop likely reflects typical volatility in a low-priced SPAC rights security or reaction to a delayed or unreported corporate event.

Artius II Acquisition Inc. Rights (AACBR) is a thinly traded security tied to a SPAC structure, which is inherently volatile and prone to sharp daily swings on minimal volume. The absence of any reported news in the 48 hours before this decline means the move was not triggered by a specific named catalyst such as earnings, merger news, or regulatory action. For SPAC-affiliated instruments, common drivers of unexplained declines include shifts in redemption assumptions, broader liquidity concerns in the SPAC market, technical selling in a low-float security, or news that circulated outside major financial newswires and was not captured in the Yahoo Finance RSS feed. Without access to trading volume, float size, or contemporaneous market commentary, we cannot determine whether this was organic selling pressure or mechanical deleveraging.

CISS

C3is Inc. - Common StockIndustrials

$0.09−$0.02

-18.5%

NASDAQ · Mkt cap $4.6 M

No news headlines were found in the last 48 hours, so the 18.5% decline in CISS cannot be attributed to a specific reported event; the drop likely reflects technical selling, broader market sentiment, or unannounced developments.

The absence of any news coverage in the prior 48 hours means we cannot point to a concrete catalyst such as earnings, regulatory action, or corporate announcement. CISS is a micro-cap stock trading at $0.09, a price range where liquidity is typically thin and volatility is high. Stocks at this valuation tier are sensitive to several generic pressures: technical selling tied to support breaks or algorithmic liquidations, broad market weakness affecting small-cap sentiment, short-seller activity or rumors not yet reflected in formal news, insider transactions, or delayed disclosure of material events not yet indexed by news aggregators. Without headlines to anchor our analysis, we cannot distinguish between these possibilities. A stock in this price range may move sharply on minimal volume and sentiment shifts that do not generate immediate news coverage.

BrightView Holdings IncIndustrials

$13.09−$2.47

-18.3%

NYSE · Mkt cap $1.0 B

BrightView missed Q2 revenue expectations with only 1.3% year-over-year sales growth to $717.6 million, triggering an 18% stock drop on disappointing earnings results.

BrightView reported Q2 2026 earnings on August 4th that fell short of Wall Street's sales forecast. The headline explicitly states the company "missed Wall Street's revenue expectations" with sales growing just 1.3% year-on-year. This weak top-line growth for a mature landscaping services company signals operational challenges or market softness. While one headline mentions "second consecutive quarter of land maintenance revenue growth," the lead story emphasizes the miss against consensus estimates, which is typically what drives sharp single-day declines. The stock's 18% drop ranks it among the day's 25 biggest losers, consistent with a significant earnings disappointment. No positive guidance revision or offsetting metric is highlighted to counterbalance the revenue miss.

PMI

Picard Medical, Inc.Healthcare

$4.30−$0.95

-18.2%

NYSE · Mkt cap $6.8 M

PMI fell 18.19% with no news headlines in the last 48 hours, making the specific cause unclear; the drop may be tied to earnings, guidance, clinical trial results, or broader sector weakness.

No recent news headlines are available to explain PMI's sharp 18 percent decline. Without earnings announcements, FDA decisions, clinical outcomes, or other company-specific catalysts in the provided information, the root cause remains unknown. For a medical device or diagnostics company like Picard Medical, typical drivers of large single-day drops include disappointing quarterly results or guidance reductions, adverse clinical trial data or regulatory setbacks, loss of a major customer or contract, short-covering reversals, or broad-market selloffs in healthcare stocks. The 18 percent magnitude suggests something material rather than technical noise, but without corroborating headlines the specific event cannot be determined from this snapshot alone.

TWG

Top Wealth Group Holding Limited Ordinary SharesConsumer Defensive

$1.49−$0.32

-17.5%

NASDAQ · Mkt cap $22 M

No news headlines were found in the last 48 hours to explain the 17.45% decline in TWG stock on August 4, 2026, suggesting the move was driven by unreported market factors, technical selling, or delayed news dissemination.

Without recent news headlines to reference, the cause of TWG's sharp 17.45% drop cannot be directly attributed to a specific corporate event, earnings announcement, regulatory action, or market development reported in the last 48 hours. Stocks in the investment or wealth management sector can be sensitive to macroeconomic shifts, changes in asset under management, client redemptions, regulatory concerns, or insider trading activity. The absence of news coverage does not rule out that a catalyst exists; it may indicate the market moved on information not yet picked up by major financial news feeds, or that the decline resulted from technical factors such as stop-loss triggering, options expiration effects, or general sector rotation out of financial services equities. Without access to company filings, insider transactions, or real-time market commentary, the specific driver remains unknown.

JDZG

JIADE LimitedConsumer Defensive

$3.21−$0.67

-17.3%

NASDAQ · Mkt cap $23 M

JDZG dropped 17.27% on August 4, 2026, but no news headlines were published in the last 48 hours, so the specific catalyst cannot be identified from available reporting.

The absence of any news coverage in the last 48 hours means the decline cannot be attributed to a company announcement, earnings report, regulatory action, or other disclosed event. JDZG is a small-cap equity with limited analyst coverage, which can make it prone to sharp moves on limited volume or undisclosed developments. The move could reflect several unstated catalysts: deterioration in fundamentals or guidance announced through channels not yet indexed by major news feeds, sector-wide weakness affecting small Chinese equities, technical selling or forced liquidations, or market response to rumors or social media activity not yet reported by mainstream financial media. Without headlines or company disclosure, determining the root cause requires additional sources beyond what is provided here.

TWLVR

Twelve Seas Investment Company III Rights

$0.17−$0.03

-16.8%

NASDAQ

No news headlines were found in the last 48 hours, so the 16.81% decline likely reflects either technical/market-driven selling or company-specific developments not yet captured in major news feeds. SPAC-related rights offerings are particularly prone to valuation pressure as expiration nears.

Twelve Seas Investment Company III Rights is a SPAC rights instrument, a category of security with inherent structural vulnerabilities. Rights offerings have defined expiration dates and redemption values, making them highly sensitive to changes in the underlying SPAC's prospects, merger timing uncertainty, or redemption deadline approaches. The absence of news headlines does not mean nothing happened; it may indicate that the move was driven by technical factors, internal redemption dynamics, or a development not yet reported by major financial news sources. Alternatively, investors may be unwinding positions ahead of a known deadline or in response to broader SPAC market sentiment deterioration. Rights are also thinly traded, meaning smaller volume shifts can produce outsized percentage moves.

INTJ

Intelligent Group LimitedIndustrials

$2.50−$0.50

-16.7%

NASDAQ · Mkt cap $5.0 M

No news headlines were found in the last 48 hours for INTJ, so the 16.69% drop likely stems from a technical breakdown, sector rotation, or undisclosed company-specific event not yet covered by financial news feeds.

The absence of recent news headlines is notable given the stock's significant single-day loss, ranking it among the day's 30 biggest losers. In such cases, the decline could reflect several possibilities: a delayed earnings report or guidance revision that hasn't yet been syndicated through major news feeds, a sector-wide selloff affecting smaller-cap stocks disproportionately, technical breakdown below a key support level triggering algorithmic selling, or insider activity not yet public. Smaller companies listed on NASDAQ are sometimes subject to sharper moves on lower volume with minimal media coverage. Without access to intraday trade data, company announcements on the IR website, or breaking news sources beyond the 48-hour window provided, the specific driver remains unknown. The lack of news suggests either the catalyst occurred outside the tracked window or the move was technically or sentiment-driven rather than event-driven.

SHOTR

RMG ML Sports Holdings Rights

$0.15−$0.03

-16.7%

NASDAQ

No news headlines were published in the last 48 hours for SHOTR, so the 16.67% drop cannot be directly attributed to a specific event. The decline likely reflects typical volatility in thinly-traded rights offerings or broader sentiment shifts in the microcap space.

The absence of recent headlines means we cannot point to a specific catalyst such as earnings, guidance, regulatory action, or corporate news. SHOTR is a rights offering related to RMG ML Sports Holdings, which typically trades with very low liquidity and tight fundamentals. Stocks in this category often experience sharp single-day moves on minimal volume that may reflect technical factors, institutional rebalancing, or delayed market reaction to older news. Without access to intraday trading data or a clear triggering event, we cannot definitively explain this particular decline. The move could be driven by broader weakness in microcap equities, a delayed reaction to news from more than 48 hours ago that Yahoo Finance did not capture, or simply low-liquidity price action that does not require a catalyst.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.04−$0.01

-16.7%

NASDAQ · Mkt cap $1.1 M

No news headlines were found in the last 48 hours, so the 16.67% drop likely stems from technical selling, low-volume price pressure, or unannounced company developments in a microcap stock with minimal liquidity.

The absence of any reported news in the last 48 hours makes it impossible to attribute the move to a specific catalyst like earnings, product announcements, or regulatory actions. WTER is a microcap equity trading at $0.04 per share, a price point where stocks are highly susceptible to thin trading volume, momentum reversals, and outsized percentage moves on small absolute dollar flows. The stock ranks 32nd in biggest daily losers, suggesting broad selling pressure. Possible underlying causes include delayed disclosure of negative company developments, short-seller activity targeting a low-float security, technical breakdown below a support level, or a broader retreat from speculative microcap positions. Without news coverage or identified catalyst, any explanation remains speculative.

APTV

Aptiv PLCConsumer Cyclical

$47.72−$9.54

-16.7%

NYSE · Mkt cap $9.3 B

Aptiv beat Q2 earnings but slashed full-year guidance due to prolonged weakness in China, causing the stock to fall 16.66% as investors repriced future growth expectations downward despite current quarter outperformance.

The headlines establish that Aptiv reported second-quarter 2026 earnings per share of $1.63, beating Wall Street estimates, with 2% adjusted revenue growth and 10 basis points of EBITDA margin expansion. However, the company simultaneously lowered its full-year 2026 outlook citing weaker automotive production and prolonged weakness in the Chinese market. Multiple sources confirm this was the primary driver of the decline, with one headline explicitly stating "Aptiv Shares Decline as Weak Guidance Overshadows Second-Quarter Earnings Beat." The company did secure $5 billion in new business awards, which provided partial offset, but was insufficient to counteract investor concern about sustained headwinds in automotive demand, particularly in China. The market typically punishes forward guidance cuts more heavily than it rewards backward-looking earnings beats, especially in cyclical industrial sectors like automotive suppliers.

ATXI

Avenue Therapeutics IncHealthcare

$0.30−$0.06

-16.5%

NASDAQ · Mkt cap $824 K

No news headlines were available in the last 48 hours to explain Avenue Therapeutics' 16.53% decline on August 4, 2026, so the cause remains unclear without additional context.

Avenue Therapeutics is a clinical-stage biopharmaceutical company, and biotech stocks of this profile are typically sensitive to catalysts including clinical trial results, regulatory decisions (FDA feedback letters or approvals), partnership announcements, financing events, or shifts in cash runway expectations. Without any recent headlines provided, the decline could reflect a delayed market reaction to an earlier announcement, a technical or sentiment-driven selloff unrelated to company-specific news, sector rotation out of small-cap biotech, or privately disclosed information not yet captured in public headlines. The stock's low price point ($0.30) suggests it may be under pressure from liquidity or investor confidence concerns typical of smaller biotech firms. Without concrete news, attributing the move to a specific catalyst is speculative.

CLPT

ClearPoint Neuro IncHealthcare

$12.88−$2.51

-16.3%

NASDAQ · Mkt cap $487 M

ClearPoint Neuro reported Q2 earnings on August 3 with a significant revenue miss of 16.31% and a loss surprise of 31.03% versus Wall Street expectations, triggering the 16.29% stock decline.

The earnings headlines from August 3 establish that ClearPoint Neuro substantially underperformed analyst consensus on both top and bottom lines for the quarter ended June 2026. The revenue miss of 16.31% and earnings surprise of negative 31.03% represent material shortfalls that would typically provoke investor disappointment and selling pressure. While one headline references "positive BioPharma Partner Regulatory Progress" and mentions a shift toward clinical capacity and focused ultrasound technology expansion, these forward-looking statements appear insufficient to offset the negative surprise in reported results. The timing aligns perfectly—earnings released on August 3 after market close, with the stock ranked as the 35th biggest loser the following trading day on August 4. No contradictory news or subsequent positive catalyst emerged to reverse the selling pressure within the 24-hour window.

AIN

Albany International CorpConsumer Cyclical

$62.96−$12.18

-16.2%

NYSE · Mkt cap $1.7 B

Albany International reported Q2 earnings that beat on earnings per share by 2.50% and achieved strong EBITDA, but revenue missed estimates by 3.80%, likely disappointing investors expecting more top-line growth despite operational strength.

The earnings headlines on 2026-08-04 reveal a mixed picture. Albany International did deliver an earnings surprise of plus 2.50% and achieved its strongest adjusted EBITDA in two years, driven by higher production rates in Engineered Composites. However, revenue came in 3.80% below expectations for the quarter ended June 30. In capital markets, a revenue miss can weigh heavily on investor sentiment even when bottom-line profitability metrics impress, particularly if the shortfall signals softening demand or production headwinds ahead. The stock's 16.21% decline ranks it among the day's largest losers, suggesting the market interpreted the revenue shortfall as a material disappointment that outweighed the earnings beat and EBITDA strength. The headlines do not contain forward guidance changes or management commentary on future demand, so the severity of concern appears tied primarily to the gap between revenue expectations and actual results.

VSEE

VSee Health, Inc.Healthcare

$0.09−$0.01

-16.2%

NASDAQ · Mkt cap $1.5 M

No news headlines were found in the last 48 hours, so the 16% drop on August 4, 2026 cannot be attributed to a specific announced event; the decline likely reflects either technical selling pressure, delayed market reaction to earlier news, or broad weakness in small-cap healthcare stocks.

VSee Health declined 16.17% to $0.09 with no recent news provided to explain the move. At this price level and market cap, the stock is highly illiquid and prone to sharp swings on modest volume. The lack of headlines suggests the catalyst may be indirect: either a delayed market reaction to news from before the 48-hour window, technical breakdown through support levels that triggered algorithmic selling, or broader sector weakness in telehealth or small-cap healthcare. Alternatively, an unannounced insider event, regulatory filing, or short report could have circulated outside major news channels. Without access to real-time volume data or pre-market activity, we cannot definitively separate technical capitulation from fundamental news.

Skycorp Solar Group Limited Ordinary SharesEnergy

$7.07−$1.36

-16.1%

NASDAQ · Mkt cap $5.4 M

PN Smart Energy Limited reported first half 2026 financial results on August 4th, likely triggering the 16.13% drop, though the actual results and guidance details are not provided in the headline.

A first half 2026 earnings report was published on the exact date of the stock's sharp decline, which is a natural candidate for explaining the move. However, the provided headline is only a dateline and does not include the actual financial results, guidance statements, earnings per share, revenue figures, or management commentary. The stock could have fallen due to missed earnings expectations, disappointing guidance, margin compression, project delays, or other operational concerns revealed in the full report. Without access to the actual earnings numbers and forward guidance, we cannot definitively determine whether the results themselves were weak or whether the market reacted to specific guidance cuts or industry headwinds disclosed in the earnings call. This represents a clear gap between the timing of the catalyst and the available detail.

ZSQR

Z Squared Inc.Technology

$4.32−$0.82

-16.0%

NASDAQ · Mkt cap $218 M

Z Squared announced a major acquisition of Paradox Data on August 3rd, and the 15.95% drop likely reflects investor concern about deal financing, integration risk, or dilution rather than enthusiasm for the expansion into AI infrastructure.

The company signed a definitive agreement to acquire 100% of Paradox Data and its Union County Campus, positioning itself further into AI infrastructure. On the surface, M&A can be positive, but the market's sharp 16% decline suggests skepticism. Possible investor concerns include unclear deal financing (debt versus equity issuance), potential dilution if stock is used as currency, integration execution risk, valuation questions around the acquisition price, or market worry that Z Squared is overreaching beyond its core competency. The headline itself does not disclose deal terms, purchase price, or how it will be funded, leaving material unknowns that could explain the sell-off. Without those details, investors may be pricing in risk rather than opportunity.

MGRX

Mangoceuticals, Inc. - Common StockHealthcare

$0.45−$0.09

-15.9%

NASDAQ · Mkt cap $7.2 M

Mangoceuticals announced a 180-day Nasdaq compliance extension for its minimum bid price requirement, signaling continued delisting risk and likely triggering the 15.91% decline as investors reassess the stock's viability.

The headline confirms that Mangoceuticals received an additional 180-calendar-day extension from Nasdaq to regain compliance with minimum bid price requirements. This announcement, made on the same day as the 15.91% drop, is a material negative signal. A bid price extension is not a neutral event; it publicly acknowledges that the company has failed to meet Nasdaq's listing standards and now faces a defined window to recover or face delisting. The stock's price of $0.45 appears to be trading well below the typical Nasdaq minimum of $1.00. Investors interpret such extensions as an explicit warning that the company faces significant operational or financial stress. The mention of a "Nuclea Energy Business Combination" in the headline suggests the company may be pursuing a merger or restructuring to avoid delisting, which adds uncertainty. Shareholders often sell on such announcements because delisting risk dramatically increases future volatility and liquidity concerns.

VMD

Viemed Healthcare IncHealthcare

$9.84−$1.86

-15.9%

NASDAQ · Mkt cap $341 M

Viemed Healthcare tanked 15.87% despite reporting record Q2 revenue and resumed ventilator business growth, likely because earnings per share missed estimates by 30% despite the revenue beat, signaling margin pressure or operational challenges.

The headlines present a classic disconnect: on the surface, Viemed delivered strong topline results with record revenue and a positive narrative around ventilator business recovery under the updated Medicare coverage framework. However, the earnings surprise was a sharp -30%, meaning the company missed EPS estimates significantly. The revenue beat was only +0.38%, indicating that growth is modest relative to expectations, while profitability contracted materially. This gap between revenue strength and earnings weakness typically signals rising costs, unfavorable product mix shifts, or lower-than-expected margins in the new service lines. Investors often punish earnings misses more severely than revenue beats can offset, especially in healthcare where margin sustainability is critical to valuation.

KIDZ

Classover Holdings, Inc. Class B Common StockConsumer Defensive

$0.45−$0.08

-15.8%

NASDAQ · Mkt cap $638 K

KIDZ AI announced a data center partnership with Limestone Networks to advance its GPU compute strategy, but the market sold off 15.75% despite this nominally positive infrastructure news, suggesting investor skepticism about execution or valuation.

On August 3rd, KIDZ AI published two nearly identical announcements regarding a non-binding memorandum of understanding with Limestone Networks to deploy NVIDIA Blackwell GPU infrastructure for AI inference workloads. The news framed this as a concrete operational milestone toward a $44.6 million Canopy Wave agreement. However, the stock fell sharply the following day. The disconnect between what appears to be progress on a major strategic initiative and a near-16% selloff suggests several possibilities. First, the market may view the MOU as insufficiently binding or material—non-binding MOUs carry execution risk and do not guarantee revenue. Second, the announcement may have prompted profit-taking after a prior run-up, or it may have failed to meet investor expectations for a more significant contract or partnership announcement. Third, broader market conditions, sector rotation out of AI infrastructure plays, or short-covering could be at play. Without concurrent earnings or guidance, the headline itself does not clearly explain the magnitude of the drop.

CIFR

Cipher Mining Inc.Technology

$20.39−$3.77

-15.6%

NASDAQ · Mkt cap $7.2 B

Cipher Mining reported Q2 earnings that missed revenue estimates by 15% and posted a significant loss, while regulatory delays to its Texas data center interconnection timeline clouded near-term growth prospects, triggering the 16% decline.

Cipher Mining released Q2 2026 earnings on August 4th showing revenue that lagged forecasts and a loss of -209% earnings surprise. While the company achieved operational milestones—including early Black Pearl capacity generation and completion of an $810 million secured notes offering to fund the Stingray project—these positives were overshadowed by two material headwinds. First, the earnings and revenue misses suggest underlying operational or cost challenges that disappointed the market. Second, and more significantly, a state-ordered review of interconnection timelines for several Texas-based proposed campuses introduced tangible uncertainty around the expansion pipeline that investors had been tracking. KBW maintained an Outperform rating despite the miss, but the interconnection delay appears to have spooked the stock price materially. The margin pressures and cash expense picture also missed analyst expectations, adding to the negative sentiment.

EDBL

Edible Garden AG IncorporatedConsumer Defensive

$1.91−$0.35

-15.5%

NASDAQ · Mkt cap $1.8 M

Despite announcing a multi-year private label supply agreement extending through 2028 with a major Midwest retailer on August 3, EDBL fell 15.49% the next day, suggesting the market either viewed the deal as insufficiently material, already priced in, or was reacting to an unrelated negative cata…

The timing is counterintuitive. Edible Garden released news on August 3 about expanding a partnership and broadening its private label herb program—typically positive catalysts for a small-cap agricultural company seeking revenue stability and retail scale. However, the stock dropped sharply on August 4, the day after the announcement. This disconnect suggests either the deal disappointed investor expectations relative to what was anticipated beforehand, the market has structural concerns about Edible Garden's unit economics or growth trajectory that overshadow incremental supply agreements, or a separate negative development occurred between the news release and market close on August 4 that is not reflected in the headlines provided. Without access to earnings results, guidance cuts, insider selling, or sector headwinds announced on August 4, the root cause remains unclear.

CVGI

Commercial Vehicle Group IncConsumer Cyclical

$3.89−$0.71

-15.4%

NASDAQ · Mkt cap $121 M

CVGI fell 15.43% despite beating revenue estimates and raising full-year guidance in Q2 earnings, likely due to a significant earnings miss on the bottom line where the company reported a loss versus profit expectations.

Commercial Vehicle Group reported Q2 2026 results on August 3rd that contained mixed signals. On the positive side, the company delivered revenue of $195.2 million, beating expectations by 13.77% with 13.5% year-over-year growth across all three segments, and management raised full-year 2026 revenue guidance. However, the earnings surprise was dramatically negative at -160%, indicating the company reported a substantial loss of $0.25 per share when Wall Street expected profitability. The disconnect between strong top-line execution and bottom-line deterioration appears to be the primary driver of the selloff. This suggests investors are concerned about margin pressure, operational costs, or one-time charges that offset revenue gains, despite management's claim of expanded adjusted gross margins. The market is apparently weighing the earnings miss more heavily than the revenue beat and guidance raise.

NRG

NRG Energy IncUtilities

$117.03−$21.35

-15.4%

NYSE · Mkt cap $25 B

NRG reported a significant earnings miss on August 4th despite beating revenue expectations and securing a major $500M EBITDA hyperscaler contract, triggering a 15.4% decline as the market repriced the stock despite positive forward guidance.

NRG released Q2 2026 results on August 4th showing earnings that fell 10.24% short of estimates while revenues beat by 27.02% and grew 11% year-over-year. The company simultaneously announced a transformative "bring your own power" contract with a hyperscaler targeting $500 million in annual EBITDA and reaffirmed full-year 2026 guidance and shareholder returns. Early trading on intraday headlines suggested the stock would advance on revenue strength, but the subsequent earnings miss and late-afternoon weakness in the broader energy sector (NYSE Energy Index down 0.9%) appear to have driven a severe reversal. The market likely weighted the earnings disappointment more heavily than the positive revenue beat and future contract announcement, suggesting either margin compression concerns or investor skepticism about the hyperscaler contract timing and execution risk.

BYSI

Beyondspring IncHealthcare

$0.99−$0.18

-15.4%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours, so the 15.38% decline cannot be attributed to a specific reported event; the drop likely reflects either technical selling, delayed news absorption, or sector-wide pressure on biotech stocks.

Beyondspring is a clinical-stage biopharmaceutical company, and the absence of recent news makes direct causation difficult to establish. Biotech stocks of this profile are typically sensitive to several categories of catalysts: clinical trial results or announcements, regulatory decisions from the FDA, financing events, management changes, or shifts in sector sentiment toward smaller-cap development-stage companies. Given the magnitude of the single-day drop and the lack of identified headlines, the move could reflect a delayed market reaction to older news, technical selling following a period of strength, broader biotech sector weakness, or internal company news not yet picked up by the RSS feed. Without specific evidence, assigning causation is speculative.

FXHO

Utime Ltd.Technology

$9.74−$1.73

-15.0%

NASDAQ · Mkt cap $54 M

No news headlines were found in the last 48 hours for FXHO, so the 15% decline cannot be directly attributed to a reported event. The drop likely reflects a market-wide selloff, technical break, or undisclosed company-specific development.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to tie this significant 15% decline to a specific catalyst. For a NASDAQ-listed company, such a sharp move typically correlates with earnings surprises, guidance revisions, insider trading activity, analyst downgrades, or sector-wide weakness. Without access to real-time news wires, earnings calls, SEC filings, or social media discussion, the exact trigger remains unknown. It is possible the news simply has not yet propagated to the RSS feed checked, or the move was driven by technical factors rather than fundamental news. The stock's relatively modest price point of $9.74 may suggest it is either a smaller-cap company or a distressed equity, both of which can experience sharp intraday moves on thin volume or small catalysts.

LVWR

Livewire Group IncConsumer Cyclical

$1.42−$0.25

-14.7%

NYSE · Mkt cap $254 M

A custom motorcycle partnership announcement with Gas Monkey Garage on the morning of August 4 does not clearly explain a 14.71% intraday drop; the move likely reflects broader market or company-specific headwinds unrelated to the published news.

The only recent headline is a product announcement—a partnership with Richard Rawlings and Gas Monkey Garage to build a custom electric motorcycle for a flat track race class. This is a niche marketing and sponsorship effort that would typically be viewed as positive brand exposure for an electric two-wheeler company, not as a catalyst for a sharp 49th-biggest daily loss. The timing is suspicious: the news dropped at 12:00 UTC on August 4, yet the stock fell 14.71% during the same day, suggesting either the market reacted negatively to execution or visibility concerns, or—more likely—the drop was driven by separate factors (sector rotation, short covering reversal, a missed earnings or guidance announcement not captured in the RSS feed, or broader market weakness) that the headline does not address. Without access to earnings reports, analyst downgrades, or company guidance changes from the past 48 hours, the root cause remains unclear.

ACH

Aluminum Corp of China LtdHealthcare

$2.92−$0.49

-14.2%

NYSE · Mkt cap $102 M

No headlines were published in the last 48 hours to explain ACH's 14.24% drop, so the cause remains unclear; weakness may stem from commodity price pressure, broader China equity concerns, or technical selling.

The absence of any news in the 48 hours preceding this sharp 14.24% decline makes it difficult to pinpoint a specific catalyst. Aluminum Corp of China, as a commodity producer with significant exposure to Chinese economic cycles and global aluminum prices, could have been affected by several types of events that may not yet have surfaced in headline form: a weakening in global aluminum demand or prices, disappointing data on Chinese industrial production or exports, broader weakness in China-listed equities, or technical selling pressure from recent outperformance. The rank as the 50th biggest loser suggests this was a material decline but not the most extreme move of the day, consistent with a commodity stock responding to sector headwinds rather than company-specific news.